CN116676285A

CN116676285A - Carbonyl reductase mutant for preparing chiral alcohol compound and application thereof

Info

Publication number: CN116676285A
Application number: CN202310470911.XA
Authority: CN
Inventors: 倪国伟; 尚中栋; 郭元勇; 袁培斋; 高全喜; 张数; 郜宪兵; 高青磊
Original assignee: Shandong Huanjiang Biopharmaceutical Co ltd
Current assignee: Shandong Huanjiang Biopharmaceutical Co ltd
Priority date: 2021-09-29
Filing date: 2021-09-29
Publication date: 2023-09-01
Also published as: CN113801859A; CN113801859B; CN116445436A

Abstract

The invention relates to a carbonyl reductase mutant and application thereof, wherein the carbonyl reductase mutant is prepared by the steps of: 2 in the presence of the following mutations: v at position 45 is mutated to I (V45I); the G at position 141 was mutated to V (G141V, I195L), and the I at position 195 was mutated to L (I195L). When the carbonyl reductase mutant is used for synthesizing chiral alcohol, the substrate concentration can reach more than 100g/L, and the carbonyl reductase mutant has stereoselectivity as high as 99.5 percent, high enzyme activity and good catalytic efficiency. Compared with chemical synthesis, the method of the invention obviously reduces or eliminates the use of various polluting chemicals, thereby obviously reducing the environmental pollution risk. The specific carbonyl reductase mutant is selected, the enzyme activity is high, the stereoselectivity is good, the production efficiency is greatly improved, the production cost is reduced, and the method is suitable for large-scale industrial production.

Description

Carbonyl reductase mutant for preparing chiral alcohol compound and application thereof

Technical Field

The invention belongs to the fields of enzyme engineering and organic synthesis, and particularly relates to a carbonyl reductase mutant for preparing chiral alcohol compounds and application thereof.

Background

The present invention is a divisional application of CN 202111154268.7.

Chiral diol compounds are key intermediates used in targeted liver drugs and have been used in a number of clinical and preclinical studies. Such as perafuwei mesylate, which is currently being developed by the western medicine corporation of new general, has completed clinical stage two and is currently being developed in clinical stage three. The key diol intermediates all adopt chemical synthetic routes.

The preparation process is reported in patent document US20030225277, the process route being as follows:

the technical scheme needs to use an organic catalyst (+) -DIPCl, the catalyst is high in price, the process operation is complex, and the catalyst is difficult to apply to large-scale production. The chiral purity of the diol compound prepared by the process route is 98%, and in order to meet registration requirements, the chiral purity of the diol compound needs to be refined, so that the production cost is further increased, and the production cost of the whole route is higher, so that a preparation method meeting commercial production is urgently needed.

There are many references in the art to reduce carbonyl groups using carbonyl reductase enzymes and mutants thereof. Carbonyl reductase can realize high stereoselectivity of carbonyl and has wide application in preparing chiral alcohol. The problems to be solved are mainly high enzyme activity and stereoselectivity.

CN112941043 discloses a carbonyl reductase and mutant thereof, which can be used for preparing chiral β' hydroxy- β -amino acid; CN112626144a discloses a biosynthetic method for the preparation of tenofovir intermediates, using carbonyl reductase; CN112359028A discloses a carbonyl reductase, which is obtained by inoculating and fermenting an enzyme-producing strain Escherichia coli TM 1908.

CN102482648A discloses a ketoreductase with good stereoselectivity for preparing α -chlorohydrin. The conversion rate and the stereoselectivity are high, but the enzyme activity is insufficient, and the actual requirements cannot be met. In particular to industrialized large-scale preparation.

CN108753851a discloses a method for preparing chiral mono-hydroxy derivatized chiral alcohols with carbonyl reductase as a biocatalyst, which uses carbonyl reductase ChKRED12 with accession number KC342012 in NCBI database.

However, when a substrate of a specific structure is reduced by using carbonyl reductase known in the prior art, there is a case that the activity of the enzyme is insufficient, which is not conducive to large-scale industrial production. The price of the enzyme is relatively high, and the enzyme activity severely restricts whether the industrialization can be realized.

Disclosure of Invention

Aiming at the defect of insufficient enzyme activity when carbonyl reductase in the prior art prepares chiral diol compounds, particularly the (S) -1- (3-halophenyl) -1, 3-propanediol serving as a paladefovir intermediate, the invention provides a carbonyl reductase mutant which has higher enzyme activity and excellent stereoselectivity and provides industrialized convenience for the enzyme synthesis of the (3-halophenyl) -1, 3-propanediol medical intermediate.

The first object of the present invention is to provide a carbonyl reductase mutant which is produced by a method corresponding to the sequence of SEQ ID NO:2 in the presence of one or a combination of more than two of the following mutations: v at position 45 is mutated to I (V45I), K at position 63 is mutated to Q (K63Q), G at position 141 is mutated to A (G141A), G at position 141 is mutated to V (G141V), I at position 195 is mutated to L (I195L), and A at position 204 is mutated to V (A204V).

Further, the carbonyl reductase mutant is a mutant corresponding to SEQ ID NO:2 in the presence of one of the following mutations:

(i) The G at 141 is mutated to A (G141A), and the I at 195 is mutated to L (I195L), the amino acid sequence of which is shown in SEQ ID No:4 is shown in the figure;

(ii) The G at 141 is mutated to V (G141V), and the I at 195 is mutated to L (I195L), the amino acid sequence of which is shown in SEQ ID No: shown at 6.

(iii) V at position 45 is mutated to I (V45I); the G at 141 is mutated into V (G141V, I195L), the I at 195 is mutated into L (I195L), and the amino acid sequence is shown in SEQ ID No: shown as 8;

(iv) V at position 45 is mutated into I (V45I), G at position 141 is mutated into V (G141V, I195L), I at position 195 is mutated into L (I195L), A at position 204 is mutated into V (A204V), and the amino acid sequence is as shown in SEQ ID No:10 is shown in the figure;

(v) V at position 45 is mutated to I (V45I), K at position 63 is mutated to Q (K63Q), L at position 118 is mutated to M (L118M), G at position 141 is mutated to V (G141V, I195L), A at position 204 is mutated to V (A204V), and the amino acid sequence thereof is as shown in SEQ ID No: shown at 12.

SEQ ID NO:2 is derived from the carbonyl reductase nak red of Novosphingobium aromaticivorans, reference CN102482648, the inventors unexpectedly found that the amino acid sequence of the enzyme sequence of SEQ ID NO:2 into specific amino acid, and when the substrate of the formula (IV) is used for preparing the formula (V), the enzyme activity is high, the conversion rate is high, and the stereoselectivity is good.

The carbonyl reductase mutant provided by the invention also comprises the following ranges: 4, 6, 8, 10 or 12, and performing one or more amino acid substitutions, deletions, alterations, insertions or additions to the amino acid sequence shown in SEQ ID No. 4, 6, 8, 10 or 12 within the range of maintaining enzyme activity; or (b)

4, 6, 8, 10 or 12, performing insertion of one or more amino acids at the N end or the C end of the sequence within the range of maintaining the enzyme activity, wherein the number of inserted amino acid residues is 1-20; preferably 1 to 10, more preferably 1 to 5.

In the method for producing the enzyme, alcohol dehydrogenase or glucose dehydrogenase or formate dehydrogenase which realizes coenzyme regeneration and a target gene are constructed on the same plasmid pET28a (+) vector, and then introduced into an expression host E.coli, and the expression is induced to obtain a cell containing the target enzyme. The cell can be obtained directly by centrifugation, and the cell wall is broken to obtain crude enzyme liquid or crude enzyme powder which is used for subsequent bioconversion reaction.

The second object of the present invention is to provide a method for preparing chiral diol compounds, comprising the steps of:

taking a compound of the formula IV as a substrate, and carrying out asymmetric reduction reaction under the catalysis of carbonyl reductase in the presence of coenzyme to obtain a compound of the formula V;

wherein the R groups are selected from

At least one of (a) and (b); x is selected from F, cl, br,I。

The carbonyl reductase is added in a form of thalli, crude enzyme liquid, crude enzyme powder or pure enzyme.

Preferably, the concentration of the substrate, i.e. the compound of formula VI, in the reaction system is 50-200 g/L; more preferably 100 to 150g/L.

Preferably, the carbonyl reductase is used in an amount of 1wt% to 6wt% to the substrate mass ratio, such as when added as wet cells, the mass ratio of the added wet cells to the substrate mass is 30wt% to 100wt%, preferably 50wt% to 70wt%.

Further, in the reaction system, a co-substrate is also present, the co-substrate being selected from the group consisting of: at least one of isopropanol, glucose, ammonium formate; preferably, the concentration of the co-substrate is 100-200% of the substrate concentration, preferably the concentration of the co-substrate is 140-170% of the substrate concentration.

Further, the preparation is carried out in a phosphate buffer salt system, and the pH is 6-9, preferably 6.5-8.5, more preferably 7.0-7.5; and/or

The reaction temperature is 10 ℃ to 50 ℃, preferably 20 ℃ to 40 ℃, more preferably 25 ℃ to 35 ℃; and/or

The reaction time is 0.1 to 240 hours, preferably 0.5 to 120 hours, more preferably 1 to 72 hours, still more preferably 3 to 10 hours.

Further, the coenzyme refers to a coenzyme capable of realizing electron transfer in oxidation-reduction reaction; comprises at least one of reduced coenzyme and oxidized coenzyme; the reduced coenzyme is selected from NADH, NADPH, or a combination thereof; the oxidized coenzyme is selected from NAD ⁺ 、NADP ⁺ Or a combination thereof.

Further, the ratio of the amount of the coenzyme to the amount of the substrate is 0.01 to 1.0wt%, preferably 0.01 to 0.5wt%.

Further, in the reaction system, the carbonyl reductase is an enzyme in a free form, an immobilized enzyme, or an enzyme in a bacterial form.

Further, the gene of the carbonyl reductase and/or the enzyme for coenzyme regeneration is constructed on an expression vector.

Further, in the reaction system, there is also an enzyme for coenzyme regeneration, specifically selected from alcohol dehydrogenase, formate dehydrogenase, glucose dehydrogenase, or a combination thereof.

The conversion of the substrate compound of formula (IV) to the product compound of formula (V) under the catalysis of the carbonyl reductase of the invention is above 70%, preferably above 85%, more preferably above 95%, most preferably above 99%; the ee value of the compound of formula V is 90% or more, more preferably 95% or more, and still more preferably 99% or more.

In another preferred embodiment, in step (b), the separating comprises: isopropanol was added, the cells were centrifuged, partially concentrated, extracted with methyl tertiary ether, and the organic layer was concentrated.

The invention has the main advantages that:

(1) The invention is suitable for industrialized production of the compound of the formula V with high chemical purity and high optical purity, and then further subsequent reaction is carried out to prepare the (S) -1- (3-chlorphenyl) -1, 3-propanediol.

(2) The method and the catalytic reduction reaction system have stereoselectivity as high as 99.5 percent, high tolerance to organic solvents and substrate, high catalytic activity and substrate concentration of more than 100g/L, so that mass production can be carried out under higher substrate concentration.

(3) Compared with chemical synthesis, the method of the invention obviously reduces or eliminates the use of various polluting chemicals, thereby obviously reducing the environmental pollution risk. The specific carbonyl reductase mutant is selected, so that the enzyme activity is high, the stereoselectivity is good, the production efficiency is greatly improved, and the production cost is reduced. The method only needs extraction operation for post-treatment, and is simple to operate.

Drawings

FIG. 1 is a chiral pattern of racemates of compounds of formula V;

FIG. 2 is the sequence of example 1 set forth in SEQ ID NO:4, preparing a chiral pattern of the compound of formula V by using a carbonyl reductase mutant of the amino acid sequence;

FIG. 3 product obtained in example 3 ¹ HNMR profile.

Detailed Description

The following description further illustrates the present invention in terms of embodiments, but it should be understood that the description of embodiments is not to be construed as limiting the present invention.

Preparation exampleConstruction of carbonyl reductase engineering bacteria and carbonyl reductase homologous mutation library

Cloning 5 carbonyl reductase enzyme genes from WO03 carbonyl reductase enzyme genes and mutant genes thereof into a pET28a (+) vector, then introducing into host escherichia coli BL21, and obtaining recombinant genetically engineered bacteria of carbonyl reductase through induction expression.

Wild carbonyl reductase WO03 (with the nucleic acid sequence shown as SEQ NO.1 and the amino acid sequence shown as SEQ NO. 2) is used as a template, and a random point mutation kit is usedII Site-Directed Mutagenesis Kit) to perform error-prone PCR or mutating a wild-type carbonyl reductase gene by directed evolution to obtain a plasmid library comprising the evolved carbonyl reductase gene. The constructed plasmid library was transferred into E.coli BL21 (DE 3) (cat# kang century CW 0809S) and cultured overnight in an oven at 37℃on LB solid medium containing 50. Mu.g/mL kanamycin. Single colonies were picked into 96-well plates containing 400. Mu.L of LB liquid medium (containing 50. Mu.g/mL kanamycin), cultured at 37℃overnight at 200rpm, and seed solutions were obtained. Then 10. Mu.L of the seed solution was transferred to a 96-well plate containing 400. Mu.L of fermentation medium (containing 50. Mu.g/mL kanamycin) and incubated at 37℃to OD600>0.8. Then isopropyl thiogalactoside (IPTG) with the final concentration of 1mM is added, the temperature is reduced to 28 ℃ to induce the expression of the mutant, and the culture is continued for 20 hours. After the fermentation was completed, the cells were collected by centrifugation at 4000g for 30min, and then resuspended in 200. Mu.L of lysis buffer (0.1M phosphate buffer containing 1000U of lysozyme, pH 7.0) and lysed at 30℃for 1h. After lysis was completed, the supernatant was centrifuged at 4000g at 4℃for 30min and clarified supernatant was used to determine mutant activity. mu.L of the reaction solution (containing 0.4mM substrate, 1mM NADH, 40. Mu.L of dimethyl sulfoxide) was added to a new 96-well plate, followed by 1 additionAfter 0. Mu.L of the supernatant, the change of NADH was detected at 340nm, and the consumption of NADH was measured in response to the level of the mutant enzyme activity, and the carbonyl reductase mutants shown in Table 1 below were obtained by screening.

TABLE 1

Example 1

Screening carbonyl reductase by using the compound IV as a substrate, wherein the screening method and the screening result are as follows;

the detection method of the reaction conversion rate comprises the following steps: phenomenex Gemini C18, 4.6×250mm 5 μm); mobile phase A is 10% acetonitrile, mobile phase B is acetonitrile, and gradient elution is carried out according to the following table; the flow rate is 1.0ml per minute; the column temperature is 30 ℃; the detection wavelength was 220nm.

The chiral monitoring method of the compound V is as follows: chromatographic column: macroxylonite IB-3,5 μm, 4.6X250 mm; mobile phase: isopropanol: n-hexane=10:90; the flow rate is 1.0mL/min; run time: 20min; column temperature is 30 ℃; detection wavelength: 220nm. S configuration 10min and R configuration 13min.

The results are shown in Table 2 below:

TABLE 2

Enzyme numbering	Conversion rate	e.e. value	Configuration of
				WO03(SEQ ID No.2) ^[a]	98.9％	99.80％	S
LSADH ^[b]	21.3％	93.78％	R
				LK ^[b]	12.4％	38.52％	S

Note that: carbonyl reductase LSADH is derived from Leiffsonia sp.Strain S749, accession number AB213459, carbonyl reductase LK is derived from Lactobacillus kefir, reference WO 2010/025238.

Reaction conditions (a) 1g IV compound, 0.2g wet cell, 0.001g NADP+,0.1g GDH wet cell, 1.5g glucose and 10ml phosphate buffer (100 mM, pH 7.0) were shake-reacted at 30℃and 220rpm for 24h; (b) 1g of IV compound, 0.2g of wet cells, 0.001g of NAD+,20% isopropyl alcohol and 10ml of phosphate buffer (100 mM, pH 7.0) were subjected to shaking reaction at 30℃and 220rpm for 24 hours.

It can be seen that the carbonyl reductase has conversion rate and stereoselectivity which are not suitable for large-scale production of key intermediate (S) -1- (4-chlorophenyl) -1, 3-propanediol except WO03 (the amino acid sequence of which is shown as SEQ ID No.2, and the encoding gene of which is shown as SEQ ID No. 1) can not meet the requirement of industrial production, but the enzyme activity of carbonyl reductase WO03 is not high enough, so that the carbonyl reductase mutant with excellent enzyme activity, conversion rate and stereoselectivity is screened by taking the carbonyl reductase of WO03 as a basis to mutate the carbonyl reductase.

As the reaction system, wet cells, crude enzyme solution, crude enzyme powder, pure enzyme, etc. of the above carbonyl reductase can be used. In order to obtain a high conversion efficiency, it is preferable to use a crude enzyme solution or wet bacterial cells. The ratio of the amount of carbonyl reductase to the mass of the substrate is preferably 1wt% to 6wt% or the ratio of the mass of resting cell cells to the mass of the substrate is 10wt% to 100wt%.

Example 2:

inoculating recombinant genetically engineered bacteria stored in glycerol in preparation example 1 into LB liquid medium containing 100ug/ml of ammonia-gas-phase mycin, culturing at 37℃ and 220rpm for 12-16h to obtain seed culture medium, inoculating the seed liquid into liquid medium containing 100ug/ml of ammonia-gas-phase mycin resistance at a ratio of 1.5%, and culturing at 37deg.C and 220rpm to OD ₆₀₀ Value of>2.0, adding lactose with the final concentration of 1.0%, cooling to 25 ℃, continuously culturing for 2 hours, adding lactose with the final concentration of 0.5%, culturing for 20 hours, placing in a tank, and centrifuging to obtain thalli which are used as a catalyst for bioconversion. According to reaction conditions (a) of example 1, namely: 1g of the IV compound, 0.3g of wet cells, 0.001g of NADP+,0.1g of GDH wet cells, 0.2g of glucose and 10ml of phosphate buffer (100 mM, pH 7.0) were reacted at 30℃with a shaking table at 220rpm for 24 hours to prepare the compound V. The resulting library of carbonyl reductase homologous mutations was screened and the results are shown in table 3 below:

TABLE 3 Table 3

Because of the degeneracy of the codons, the nucleic acid sequences of the carbonyl reductase mutants as described above are not limited to the nucleic acid sequences listed in table 3. Homologs of the base sequence can be obtained by a person skilled in the art by appropriate introduction of substitutions, deletions, alterations, insertions or additions, and the present invention covers such homologs as long as the expressed recombinase thereof retains catalytic reduction activity on the IV compound. The homolog of the polynucleic acid according to the invention can be obtained by substitution, deletion or addition of one or more bases of the base sequence within a range that retains the enzymatic activity.

Preferably, the invention provides carbonyl reductase mutants with amino acid sequences shown as SEQ ID No. 4, 6, 8, 10 or 12, which have obviously improved enzyme activity compared with wild type enzyme WO03, and the stereoselectivity to S configuration can reach more than 99%.

Definition of enzyme Activity: in a 50ml centrifuge tube, weighing 0.5g of substrate, adding 1.5ml of isopropanol, adding 3.5ml of phosphate buffer with pH of 6.0-6.5, weighing 0.025g of coenzyme NAD, preheating the system in a water bath kettle at 30 ℃ for 15min, weighing 0.5g of thalli, adding the reaction system, putting the reaction system in a shaking table at a constant temperature of 30 ℃ for 150rpm, and starting timing for 1h. After completion, 0.1ml of the reaction solution was rapidly removed by a pipette in a shaking-up state, added to a 10ml centrifuge tube, and then 4.9ml of isopropyl alcohol was added and thoroughly mixed by a pipette. Centrifuge for 10min at 3500rpm. Pouring the supernatant into a sampling tube, and detecting the conversion rate, namely the enzyme activity.

Example 3 biocatalytic preparation of Compound V (R=Et)

100g of Compound IV (R=Et) was weighed into a 3L four-necked flask, 1.0L of 0.1mol/L phosphate buffer pH7.0 was added, 158.4g of glucose was added, and the mixture was stirred well, 10g of GDH wet cell, 52.3g of carbonyl reductase mutant WO08 wet cell, NAD was added ⁺ 0.2g, placing in a 35 ℃ water bath, reacting under mechanical stirring at 220rpm, measuring the pH value of the reaction solution to be about 5.6 after half an hour, regulating the pH value to be 7.2 by using a saturated sodium carbonate solution, measuring the pH value of the reaction solution to be about 6.4 after half an hour,the pH is adjusted to 7.1 by saturated sodium carbonate solution, and then the pH value is continuously monitored, and the pH value is basically unchanged and is kept between 6.9 and 7.0. The reaction was carried out for 10h, the reaction was terminated by monitoring the remaining 0.55% of the starting material by HPLC, 1.5L of ethyl acetate was added, stirred for about 10min, then the liquid was separated, the aqueous layer was extracted with ethyl acetate, 500 mL. Times.2, the ethyl acetate was combined, 500 mL. Times.2 was washed with saturated NaCl, and the organic phase was dried over anhydrous sodium sulfate and concentrated to give 97.1g of a pale yellow oil with a yield of 95.4%, an HPLC purity of 99.1% and an ee value of 99.9%. In the same case, the same amount of wild-type carbonyl reductase WO03 wet cell was used, and the yield was 74.8%. The products of the compounds of formula V ¹ H NMR is shown in fig. 3: (600 mhz, chloroform-d) delta 7.39 (s, 1H), 7.26 (dq, j=15.9, 7.7hz, 3H), 5.24-4.94 (m, 1H), 4.18 (q, j=7.1 hz, 2H), 3.52 (s, 1H), 2.82-2.52 (m, 2H), j=7.2 hz, 3H) 13C NMR (151 mhz, chloroform-d) delta 172.20,144.60,134.44,129.82,125.95,123.81,69.65,61.04,43.19,14.13.

The chiral pattern of compound V of the product obtained in this example is shown in FIG. 2, and the data are shown in Table 4 below:

TABLE 4 Table 4

Numbering device	Retention time (min)	Peak area	Relative content of
				1 (S configuration)	9.978	577.918	99.90
2 (R configuration)	13.095	0.571	0.10
				Total (S)		578.489	100.00

Example 4 biocatalytic preparation of Compound V (R=Me)

100g of compound IV (R=Me) was weighed into a 3L four-necked flask, 1.0L of 0.1mol/L phosphate buffer solution pH7.0 was added, 200mL of isopropyl alcohol (density 0.7855 g/mL) was added, and the mixture was stirred uniformly, 54.7g of wet cell of carbonyl reductase mutant WO07, NAD ⁺ 0.2g is placed in a 35 ℃ water bath to react under mechanical stirring at 220rpm, after half an hour, the pH value of the reaction solution is measured to be about 5.8, the pH value of the reaction solution is adjusted to be 7.0 by using a saturated sodium carbonate solution, after half an hour, the pH value of the reaction solution is measured to be about 6.4, the pH value of the reaction solution is adjusted to be 7.3 by using the saturated sodium carbonate solution, and then the pH value is continuously monitored and is kept basically unchanged, and the pH value is kept between 6.9 and 7.0. The reaction time 3h was sampled TLC to monitor the substantial disappearance of the starting material spot, HPLC to monitor the remaining 0.52% of the starting material, termination of the reaction, addition of 1.0L of ethyl acetate, stirring for about 10min, followed by separation of the aqueous layer, extraction with 500 mL. Times.2 ethyl acetate, combining of ethyl acetate, washing of 500 mL. Times.2 with saturated NaCl, drying of the organic phase over anhydrous sodium sulfate, concentration to give 92.9g of a pale yellow oil, yield 91.4%, HPLC purity 99.3%, ee 99.8%.

Claims

1. A carbonyl reductase mutant, characterized in that it is a mutant sequence corresponding to SEQ ID NO:2 in the presence of the following mutations:

(iii) V at position 45 is mutated to I (V45I); the G at 141 is mutated into V (G141V, I195L), the I at 195 is mutated into L (I195L), and the amino acid sequence is shown in SEQ ID No: shown at 8.

2. The carbonyl reductase mutant of claim 1, further comprising the following ranges: the amino acid sequence shown in SEQ ID No. 8 is obtained by carrying out substitution, deletion, change, insertion or addition of one or more amino acids within the range of maintaining the enzymatic activity; or (b)

Performing insertion of one or more amino acids at the N end or the C end of the sequence within the range of maintaining the enzyme activity on the amino acid sequence shown in SEQ ID No. 8, wherein the number of inserted amino acid residues is 1-20; preferably 1 to 10, more preferably 1 to 5.

3. The preparation method of the chiral diol compound is characterized by comprising the following steps:

carrying out asymmetric reduction reaction under the catalysis of carbonyl reductase according to claim 1 or 2 in the presence of coenzyme by using a compound of formula IV as a substrate to obtain a compound of formula V;

wherein the R groups are selected from

At least one of (a) and (b); x is selected from F, cl, br, I.

4. The method according to claim 3, wherein the carbonyl reductase is added in a form selected from the group consisting of bacterial cells, crude enzyme liquid, crude enzyme powder and pure enzyme.

5. The process according to claim 3, wherein the concentration of the substrate, i.e. the compound of formula VI, in the reaction system is 50 to 200g/L; more preferably 100 to 150g/L; the ratio of the amount of carbonyl reductase to the mass of the substrate is preferably 1wt% to 6wt%.

6. A method of preparing according to claim 3, wherein a co-substrate is also present in the reaction system, said co-substrate being selected from the group consisting of: at least one of isopropanol, glucose, ammonium formate; preferably, the mass concentration of the co-substrate is 100-200% of the substrate concentration, preferably the concentration of the co-substrate is 140-170% of the substrate mass concentration.

7. A process according to claim 3, wherein the reaction is carried out in a phosphate buffer salt system, having a pH of 6-9, preferably 6.5-8.5, more preferably 7.0-7.5; and/or

8. The method according to claim 3, wherein the coenzyme is a coenzyme capable of electron transfer in a redox reaction; comprises at least one of reduced coenzyme and oxidized coenzyme; the reduced coenzyme is selected from NADH, NADPH, or a combination thereof; the oxidized coenzyme is selected from NAD ⁺ 、NADP ⁺ Or a combination thereof;

preferably, the ratio of the amount of coenzyme to the amount of substrate is from 0.01% to 1.0% by weight, preferably from 0.01% to 0.5% by weight.

9. The method according to claim 3, wherein an enzyme for coenzyme regeneration is further present, specifically selected from the group consisting of alcohol dehydrogenase, formate dehydrogenase, glucose dehydrogenase and a combination thereof.